Introduction
COPD is the third leading cause of death in the world. 1 COPD is characterized by persistent airflow restriction, which is associated with chronic airway inflammation. 2 Mainstream treatments for COPD, as recommended by international guidelines, 3 are mainly inhaled bronchodilators (IBD), including long-acting β stimulants and long-acting muscarinic antagonists, to improve respiratory function and reduce respiratory symptoms, [4] [5] [6] and inhaled corticosteroids (ICS) to reduce the frequency of exacerbations and improve the quality of life in patients with severe COPD. 5, 7, 8 However, regular treatment with ICS does not modify the long-term decline of respiratory functions and mortality in COPD. 9, 10 Combination therapy with ICS and IBD is recommended for patients with severe COPD symptoms and frequent exacerbations.
Recently, combination treatment with more than one long-acting IBD, consisting of long-acting β stimulants and long-acting muscarinic antagonists without ICS, has been reported to be more effective in improving respiratory function and symptoms, [11] [12] [13] and preventing exacerbations in severe COPD 14 than use of IBD alone. In addition, withdrawal of ICS from treatment with triple combination therapy, consisting of long-acting β stimulants, long-acting muscarinic antagonists, and ICS, does not change the risk of exacerbations. 15 This suggests that combined IBD treatment would be as effective in preventing exacerbations as triple combination therapy. Thus, the benefits of ICS in the treatment of COPD have been questioned, particularly because of the adverse side effect of ICS-caused pneumonia.
Lower respiratory infections, such as pneumonia, often occur in COPD and are known to cause COPD exacerbations, increasing the risk of mortality. 16, 17 In addition, recent clinical studies and meta-analyses have reported that ICS use increases the occurrence of pneumonia. [18] [19] [20] [21] Other studies have produced conflicting results regarding the rate of mortality from pneumonia in patients with COPD using ICS as outpatients. 18, [22] [23] [24] Thus, it is important and useful for the management of COPD to clarify the association between ICS and mortality from pneumonia in patients with COPD.
This study aimed to examine the association between ICS and mortality from pneumonia in patients with COPD by comparing in-hospital mortality between those who received ICS with IBD and those who received IBD alone.
Methods Database
We used the Japanese diagnosis procedure combination database, which contains administrative claims data and discharge abstract data from approximately 7,000,000 inpatients per year from around 1,100 hospitals across Japan. The database also includes the outpatient data of patients admitted to 426 hospitals. The database does not include data about those patients who only received outpatient treatment.
The inpatient database contains details of the primary diagnosis on admission, comorbidities present on admission, and complications occurring during hospitalization. These are recorded with the appropriate International Classification of Disease and Related Health Problems, 10th revision (ICD-10) codes accompanied by text in Japanese. This database also contains the following information on admission: dates of admission and discharge; intensive care unit admission during hospitalization; discharge status; the patient's age, sex, body height, and weight; severity of dyspnea based on the Hugh-Jones dyspnea scale; 25, 26 levels of consciousness based on the Japan Coma Scale; 27, 28 activities of daily life on admission converted to the Barthel index; 29 and severity of pneumonia based on age, dehydration, respiratory failure, orientation disturbance, and low blood pressure (A-DROP) score. 30 Details of the Hugh-Jones dyspnea scale, the Japan Coma Scale, the Barthel index, and the A-DROP score are described in the "Supplementary materials". The database also includes data on the medication and procedures the patients received during hospitalization, for example, the administration of systemic corticosteroids and intubation/ mechanical ventilation. The outpatient data contain information that includes prescription dates and the names of the drugs prescribed.
This study was approved by the Institutional Review Board of The University of Tokyo. The board waived the requirement for the patients' written informed consent because of the anonymous nature of the data.
Patient selection
Inclusion criteria for this study were as follows: 1) patients aged over 40 years, 2) those who were admitted to hospital for pneumonia (ICD-10 codes, J10-J18, J69) as the primary diagnosis between July 1, 2010 and March 31, 2013, 3) those who had a secondary diagnosis of COPD (J41-44); and 4) those who received IBD.
We excluded 1) patients who received ICS alone; 2) those who had other obstructive ventilatory impairments, including bronchiectasis (J47) and diffuse panbronchiolitis (J21); and 3) those who had pneumonia recorded as a complication during hospitalization, to preclude hospital-acquired and ventilator-associated pneumonia (J95).
Categorization by inhaled therapy
The IBD administered included tiotropium, glycopyrronium, acridinium, umeclidinium, salmeterol, formoterol, indacaterol, and vilanterol. The ICS administered included fluticasone, budesonide, mometasone, and beclomethasone. Patients who received any ICS with any IBD were defined as the ICS with IBD group. Patients who received one or more IBD but did not receive any ICS were defined as the IBD alone group.
a-DrOP score
We used the A-DROP scoring system to evaluate the severity of pneumonia. This system was established by the Japanese Respiratory Society and is similar to the CURB-65 system used by the British Thoracic Society. 30 The severity of 
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effect of inhaled corticosteroids on mortality from pneumonia in COPD pneumonia was classified into four classes using the A-DROP score: mild, 0 points; moderate, 1-2 points; severe, 3 points; and extremely severe, 4-5 points.
Outcomes
The primary outcome of this study was all-cause in-hospital mortality. The secondary outcomes were length of stay, length of intensive care unit stay, requirement for intubation/ mechanical ventilation, duration of mechanical ventilation, and mortality in patients who underwent mechanical ventilation during their hospital stay. 
Results
We identified 7,033 patients with COPD (aged 40 years) who were treated with outpatient inhaled therapy and were admitted to the hospital with pneumonia. Of them, 3,702 patients were treated with ICS and IBD, and 3,331 patients were treated with IBD alone. The patients' characteristics are shown in Table 1 . A-DROP scores in the ICS and IBD group 
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Yamauchi et al were significantly lower, and therefore their pneumonia was less severe, than in the IBD alone group.
Comorbidities on admission are presented in Table 2 . The percentage of asthma was higher in the ICS and IBD group than in the IBD alone group. The percentages of interstitial pneumonia, lung cancer, and congestive heart failure were lower in the ICS and IBD group.
The outcomes are shown in Table 3 . All-cause inhospital mortality in the ICS and IBD group was 8.1%, which was significantly lower than that in the IBD alone group (13.2%). Length of stay in the ICS and IBD group was shorter than that in the IBD alone group. The difference in the results for intensive care unit admission or requirement for mechanical ventilation was not significant between the groups. In-hospital mortality in patients who required mechanical ventilation was significantly lower in the ICS and IBD group (31.9%, n=100/313) than in the IBD alone group (39.7%, n=129/325).
The results of multivariate logistic regression analysis for all-cause in-hospital mortality associated with pneumonia in patients with COPD are shown in Table 4 . Outpatient treatment with ICS and IBD was significantly associated with lower mortality than IBD treatment alone, even after adjustment for the patients' backgrounds. Higher mortality was associated with being male, lower body mass index (BMI), severe dyspnea, poorer activities of daily living scores, and more severe pneumonia. Higher mortality was also associated with having interstitial pneumonia and lung cancer, whereas lower mortality was associated with having asthma.
Discussion
We demonstrated that in-hospital mortality associated with pneumonia in patients with COPD was significantly lower in patients treated with combined ICS and IBD therapy than IBD alone.
Previous studies have reported that the use of ICS in patients with COPD increased the occurrence of serious pneumonia requiring hospitalization. [18] [19] [20] [21] However, the association between ICS use and mortality from pneumonia in patients with COPD has remained controversial. One study demonstrated that the use of ICS was associated with an increased risk of hospitalization for pneumonia and subsequent death. 18 Several studies have reported that the use of ICS had no impact on outcomes in patients with COPD admitted with pneumonia. 19, 21, 22 Other studies have demonstrated that ICS use was associated with a decreased risk of mortality, after adjusting for potential confounders, including age, sex, 
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effect of inhaled corticosteroids on mortality from pneumonia in COPD and comorbidities. 23, 24 Furthermore, some of the previous studies 18, 19 subjected the COPD patients who were taking inhaled therapy and evaluated the mortality of pneumonia, and the others [22] [23] [24] subjected the COPD patients who were admitted with pneumonia and evaluated the effects of prior use of ICS on mortality; these latter studies were compatible with our study. However, these studies were limited because they did not adjust for the severity of pneumonia. 23, 24 Our study confirmed that the outpatient usage of ICS was associated with lower mortality than nonusage of ICS, even after adjusting for several confounders, including pneumonia severity. This indicates that treatment with ICS has protective effects against pneumonia-related mortality in patients with COPD. A possible explanation for the association between ICS and decreased mortality is that corticosteroids produce antiinflammatory effects by modulating inflammatory mediators. ICS may suppress the inflammatory response in the airway, which spreads to cause systemic inflammation. 31 It may reduce systemic inflammation by blocking excessive inflammation and the harmful effects this causes during infections. 32 Our study demonstrated that A-DROP scores in patients receiving outpatient ICS treatment were lower than those not receiving ICS. A previous study with a relatively small sample size (n=490) demonstrated that ICS use was not associated with pneumonia severity. 22 Another previous study demonstrated that the use of ICS was associated with a lower degree of pleural inflammatory effusion, 33 suggesting that ICS has a protective effect against the progression of pneumonia and related complications. Because ICS has been reported to reduce bacterial invasion into the airway epithelium in an experimental model 34 and has the potential to reduce inflammation, prior use of ICS may lead to less severe pneumonia. Our study suggests that ICS may have protective effects against the progression of pneumonia in patients with COPD.
The association between ICS and mechanical ventilation has also been controversial. 22, 24 Our study demonstrated that the percentage of patients requiring mechanical ventilation was lower in the ICS and IBD group than in the IBD alone group, although this result was not significant. Furthermore, the mortality from pneumonia in patients with COPD requiring mechanical ventilation was significantly lower in the ICS and IBD group than in the IBD alone group. These results also suggest that ICS may have protective effects against pneumonia and pneumonia-related mortality in patients with COPD.
Comorbidity of asthma was associated with decreased mortality in this study. Recently, comorbid asthma and COPD have been recognized as asthma-COPD overlap (ACO). 35 As patients with ACO have lower health-related quality of life, frequent exacerbations, and often require hospitalization, 36, 37 patients with ACO have been suggested to have a poorer long-term prognosis, when compared with patients having asthma or COPD alone. However, recent studies have demonstrated that ACO patients have better short-term mortality, compared with COPD alone. 38, 39 Our present study is consistent with the previous reports that comorbid asthma and COPD were associated with better prognosis.
Higher mortality was associated with worse general conditions at admission, including lower BMI, more severe dyspnea grade, lower level of consciousness, and poorer activities of daily life. The findings of this study were compatible with the previous study demonstrating the mortality of pneumonia in patients with COPD. 26 Further, missing data in the covariants, such as BMI and activities of daily life at admission, were also associated with higher mortality in this study. Because patients with severe conditions might not be able to get their body height and weight measured or their physical activities evaluated at admission, missing data of BMI and activities of daily life might indicate the more severe general conditions. This study has several limitations. First, the database did not contain information on the degree of airflow limitation, such as details of pulmonary function tests and COPD severity. However, the grade of dyspnea was used as a covariant of respiratory condition in this study, as a previous study had shown that dyspnea grade reflects respiratory function. 40 Second, the database did not contain information related to the dosages of the medications used. Thus, we cannot evaluate the association between mortality and the dose of ICS.
Conclusion
Outpatient inhaled therapy with ICS and IBD was associated with lower mortality from pneumonia in patients with COPD than IBD treatment alone. ICS may have protective effects against pneumonia and help prevent pneumonia-related mortality in patients with COPD.
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Supplementary materials Methods hugh-Jones dyspnea scale
The Hugh-Jones dyspnea scale is a system for grading dyspnea severity, established by Hugh-Jones and Lambert in 1952. 1 It is similar to the Medical Research Council's breathlessness scale, and is widely used in Japan. 2 The dyspnea scale is defined as follows: 1) the patient's breathing is as good as that of other people of their age and build when working, walking, and climbing hills or stairs; 2) the patient is able to walk on level ground at the pace of normal people of their age and build but is unable to maintain that pace when climbing hills or stairs; 3) the patient is unable to keep up with normal people of their age and build on level ground but is able to walk ~1.6 km or more at their own speed; 4) the patient is unable to walk more than ~50 m on level ground without resting; 5) the patient is breathless when talking or undressing or is unable to leave home because of breathlessness; (unspecified) the patient is unable to be classified into the above grades because of bedridden status.
Japan Coma scale
The Japan Coma Scale is a system widely used in Japan 3 for assessing patients' levels of consciousness and is reported to correlate well with the Glasgow coma scale. 4 The Japan Coma Scale is defined as follows: one-digit codes (1-3) are given to patients who are conscious without any stimuli; two-digit codes are assigned to patients who could be aroused by some stimuli; and three-digit codes (100-300) are given to patients in coma.
Barthel index
The Barthel index is a system for grading the activities of daily life, assessing functional status and the ability to perform daily activities. 5 It consists of ten factors: feeding, bathing, grooming, dressing, bowels, bladder, toilet use, transfer, mobility, and stairs. Scores range from 0 to 20, with a score of 20 indicating total independence, lower scores indicating increasing dependence, and 0 signifying complete dependence. It should be noted that changes of more than two points (10%) in the total score accurately reflect changes in functional status. 6 We categorized patients into four groups according to their score: completely independent (20); partially independent; ; partially dependent (13-7); and completely dependent (6-0).
